CM&R
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Medicine & Research
Volume 4, Number 2 : 138 -146
doi:10.3121/cmr.4.2.138
© 2006 Marshfield Clinic
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Falagas, M. E.
Right arrow Articles by Michalopoulos, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Falagas, M. E.
Right arrow Articles by Michalopoulos, A.

Review

The Use of Intravenous and Aerosolized Polymyxins for the Treatment of Infections in Critically Ill Patients: A Review of the Recent Literature

Matthew E. Falagas, MD, Sofia K. Kasiakou, MD, Sotirios Tsiodras, MD and Argyris Michalopoulos, MD

Matthew E. Falagas, MD; Alfa Institute of Biomedical Sciences, Athens, Greece; Department of Medicine, Henry Dunant Hospital, Athens, Greece; and Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts
Sofia K. Kasiakou, MD; Alfa Institute of Biomedical Sciences, Athens, Greece
Sotirios Tsiodras, MD; Department of Medicine, Attikon General University Hospital, University of Athens School of Medicine, Athens, Greece
Argyris Michalopoulos, MD; Intensive Care Unit, Henry Dunant Hospital, Athens, Greece

Reprint Requests: Matthew E. Falagas, MD, MSc, Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi 151 23, Greece,Tel: 30 694 61 10 000; Fax: 30 210 68 39 605, E-mail: matthew.falagas{at}tufts.edu

Intravenous and aerosolized polymyxins are being used increasingly, especially in the critical care setting, for treating patients with infections due to multidrug-resistant Gram-negative bacteria, mainly Acinetobacter baumannii and Pseudomonas aeruginosa. Recent literature suggests that intravenous colistin and polymyxin B have acceptable effectiveness for the treatment of patients with bacteremia, as well as infections of various systems and organs, including pneumonia, bacteremia, skin and soft tissue, and urinary tract infections. Although data from recent studies have suggested that the toxicity of intravenous polymyxins is probably less than reported in the older literature, caution should be taken to monitor the renal function of patients who receive these antibiotics.

Key Words: Acinetobacter • Colistin • Inhalation • Intensive care unit • Klebsiella • Multidrug-resistant Gram-negative bacteria • Nebulization • Pneumonia • Polymyxin B • Pseudomonas • Ventilator-associated




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
D. K. Burchett, W. Darko, J. Zahra, J. Noviasky, L. Probst, and A. Smith
Mixing and compatibility guide for commonly used aerosolized medications
Am. J. Health Syst. Pharm., February 1, 2010; 67(3): 227 - 230.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. Ben-Ami, R. E. Lewis, J. Tarrand, K. Leventakos, and D. P. Kontoyiannis
Antifungal Activity of Colistin against Mucorales Species In Vitro and in a Murine Model of Rhizopus oryzae Pulmonary Infection
Antimicrob. Agents Chemother., January 1, 2010; 54(1): 484 - 490.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. A Pastewski, P. Caruso, A. R Parris, R. Dizon, R. Kopec, S. Sharma, S. Mayer, M. Ghitan, and E. K Chapnick
Parenteral Polymyxin B Use in Patients with Multidrug-Resistant Gram-Negative Bacteremia and Urinary Tract Infections: A Retrospective Case Series
Ann. Pharmacother., September 1, 2008; 42(9): 1177 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
D. Landman, C. Georgescu, D. A. Martin, and J. Quale
Polymyxins Revisited
Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. E. Karageorgopoulos, T. Kelesidis, I. Kelesidis, and M. E. Falagas
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence
J. Antimicrob. Chemother., July 1, 2008; 62(1): 45 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Sarkar, E. R. H. DeSantis, and J. Kuper
Resurgence of colistin use
Am. J. Health Syst. Pharm., December 1, 2007; 64(23): 2462 - 2466.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. P. Zavascki, L. Z. Goldani, J. Li, and R. L. Nation
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1206 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
E. Meyer, F. Schwab, and P. Gastmeier
Use of very old and very new antibiotics in intensive care units in Germany
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1413 - 1415.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. R. Reinert, D. E. Low, F. Rossi, X. Zhang, C. Wattal, and M. J. Dowzicky
Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline
J. Antimicrob. Chemother., November 1, 2007; 60(5): 1018 - 1029.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by Marshfield Clinic.